Patents Assigned to AstraZeneca
  • Purine derivatives
    Patent number: 8895570
    Abstract: The invention provides the compound of formula (I) and pharmaceutically acceptable salt thereof, pharmaceutical compositions containing the compound and the use of the compound in therapy.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: November 25, 2014
    Assignee: AstraZeneca AB
    Inventors: Phillip Abbott, Roger Victor Bonnert, Thomas McInally, Stephen Thom, Hiroki Wada, Satoshi Onuma
  • GIP and exendin hybrid polypeptides
    Patent number: 8895498
    Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: November 25, 2014
    Assignees: AstraZeneca Pharmaceuticals, LP, Amylin Pharmaceuticals, LLC
    Inventors: Odile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra G. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young, Thao Le
  • Sustained release formulations using non-aqueous carriers
    Patent number: 8895033
    Abstract: The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: November 25, 2014
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Mary L. Houchin, Robin H. Lee, Hong Qi, Greg Oehrtman, Robert N. Jennings, Scott H. Coleman
  • Compounds and methods for treating bacterial infections
    Patent number: 8889671
    Abstract: Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: November 18, 2014
    Assignee: AstraZeneca AB
    Inventors: Gregory Steven Basarab, Madhusudhan Reddy Gowravaram, Sheila Irene Hauck, Fei Zhou
  • Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses
    Patent number: 8889692
    Abstract: The present invention relates to pyrazinone derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: November 18, 2014
    Assignee: AstraZeneca AB
    Inventors: Stephen Brough, Richard Evans, Timothy Jon Luker, Piotr Raubo
  • Methods for treating obesity employing an SGLT2 inhibitor
    Patent number: 8883743
    Abstract: Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: November 11, 2014
    Assignee: AstraZeneca AB
    Inventors: William Washburn, Jean Whaley, Mario Maidonado, James F. List, Frederick T. Fiedorek
  • Co-crystals of a triazolo [4,5-D] pyrimide platelet aggregation inhibitor
    Patent number: 8883802
    Abstract: The present invention relates to novel co-crystal forms of the compound of formula (I); wherein the co-former molecule is selected from glycolic acid, salicylic acid, decanoic (capric) acid, gentisic acid (2,5-dihydroxybenzoic acid), glutaric acid, vanillic acid (4-hydroxy-3-methoxybenzoic acid), succinic acid, malonic acid or maltol (3-hydroxy-2-methyl-4-pyrone); and to processes for their preparation, to pharmaceutical compositions containing such co-crystals, to the use of such co-crystals in the manufacture of a medicament for use in the prevention of arterial thrombotic complications in patients with coronary artery, cerebrovascular or peripheral vascular disease and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of a co-crystal of the compound of formula (I).
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: November 11, 2014
    Assignee: Astrazeneca AB
    Inventors: Stephen David Cosgrove, Matthew Jonathan Jones, Anna Polyakova-Akkus, Valeriya Nikolayevna Smolenskaya, Brenton Skylar Wolfe
  • COMBINATION TREATMENT OF CANCER
    Publication number: 20140329786
    Abstract: The present invention relates to a combination comprising AZD5363, or a pharmaceutically acceptable salt thereof, and at least one androgen receptor signalling modulator selected from MDV-3100 (also known as enzalutamide), AZD3514, abiraterone (or an ester prodrug thereof: e.g. abiraterone acetate), and bicalutamide; or a pharmaceutically acceptable salt thereof. Each of these combinations may be useful in the treatment of cancer. The invention also relates to pharmaceutical compositions comprising such combinations, and further relates to methods of treatment comprising the simultaneous, sequential or separate administration of AZD5363, or a pharmaceutically acceptable salt thereof, with at least one androgen receptor signalling modulator as described above, to warm-blooded animal, such as a human for the treatment of cancer. The invention also relates to a kit comprising such combinations.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 6, 2014
    Applicant: ASTRAZENECA AB
    Inventor: Barry Robert Davies
  • 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE
    Publication number: 20140329830
    Abstract: The present invention relates to a compound of formula (I), and to pharmaceutical compositions containing said compound and to the use of said compound in therapy, for instance in treating cognitive disorders, as well as to intermediates useful in the preparation thereof.
    Type: Application
    Filed: December 19, 2011
    Publication date: November 6, 2014
    Applicant: AstraZeneca AB
    Inventors: Helena Gybäck, Jonas Malmström, Elgaard Gitte Terp
  • Inhaler cap strap
    Patent number: 8875699
    Abstract: An inhaler (1) for dispensing doses of medicament from a container under user activation includes a body (7) which includes a mouthpiece (5) through which the medicament is dispensed and a cap (2) which can be place in a position to substantially occlude the mouthpiece (5). The cap (2) is attached to the body (7) by a strap (3) which pivots from the body (7), the cap (2) being arranged to slide on the strap (3) such that the cap (2) must translate away from the mouthpiece (5) prior to the pivoting of the strap (3).
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: November 4, 2014
    Assignee: AstraZeneca AB
    Inventor: Martin Bunce
  • Immediate release tablet formulations
    Patent number: 8871264
    Abstract: The present invention provides an immediate release pharmaceutical formulation which includes a tablet or capsule formulation comprising metformin and the sodium dependent glucose transporter (SGLT2) inhibitor dapagliflozin or its propylene glycol hydrate. The present invention also provides methods of preparing the formulations and methods of treating diseases or disorders associated with SGLT2 activity employing these formulations.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: October 28, 2014
    Assignee: AstraZeneca AB
    Inventors: Agneta Hallgren, Ralf Magnus Werner Swenson
  • Compounds and their use as BACE inhibitors
    Patent number: 8865911
    Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 21, 2014
    Assignee: Astrazeneca AB
    Inventors: Gabor Csjernyik, Sofia Karlstrom, Annika Kers, Karin Kolmodin, Martin Nylof, Liselotte Ohberg, Laszlo Rakos, Lars Sandberg, Fernando Sehgelmeble, Peter Soderman, Britt-Marie Swahn, Stefan Von Berg
  • Method for preparing adenine compound
    Patent number: 8865896
    Abstract: A method for producing adenine compound (1): wherein m and n are independently an integer of 2 to 5, R1 is C1-6 alkyl group, R2 and R3 are the same or different, and hydrogen atom, or C1-6 alkyl group, or R2 and R3 are combined with an adjacent nitrogen atom to form pyrrolidine, morpholine, piperidine, piperazine, etc., and R4 is C1-3 alkyl group, which comprises a step of reacting compound (2): and compound (3): in the presence of a boron-containing reducing agent.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: October 21, 2014
    Assignees: Astrazeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Kazuki Hashimoto, Wataru Katoda, Kazuhiko Takahashi, Ayumu Kurimoto
  • Chemical process for the synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline
    Patent number: 8865899
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: October 21, 2014
    Assignee: AstraZeneca AB
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
    Patent number: 8859570
    Abstract: The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: October 14, 2014
    Assignee: AstraZeneca AB
    Inventor: James McCabe
  • Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy
    Patent number: 8859568
    Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: October 14, 2014
    Assignee: Astrazeneca AB
    Inventors: Anders Bögevig, Yvonne Lo-Alfredsson, Donald Pivonka, Anna-Karin Tidén
  • Pharmaceutical Composition of Rosuvastatin Calcium
    Publication number: 20140294959
    Abstract: The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.
    Type: Application
    Filed: May 17, 2012
    Publication date: October 2, 2014
    Applicant: ASTRAZENECA UK LIMITED
    Inventors: Joseph Richard Creekmore, Sanjeev Huk-michand Kothari, Bradford J. Mueller, Yingxu Peng
  • COMPOUNDS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS
    Publication number: 20140296534
    Abstract: The present invention relates to novel derivatives that are suitable as precursors to compounds that are useful for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. The compounds deriving from these precursors are useful in methods of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease by positron emission tomography (PET) as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. Furthermore, the present invention also discloses the precursor compounds in crystalline form.
    Type: Application
    Filed: January 7, 2014
    Publication date: October 2, 2014
    Applicant: AstraZeneca AB
    Inventors: Seth Björk, Peter Johnström, Nils A. Nilsson, Katinka Ruda, Per M. Schou, Britt-Marie Swahn, Vern Delisser
  • TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON
    Publication number: 20140296258
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: October 31, 2013
    Publication date: October 2, 2014
    Applicant: AstraZeneca UK Limited
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Inhaler
    Patent number: D716936
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: November 4, 2014
    Assignee: AstraZeneca AB
    Inventors: Rasmus Løgstrup Jensen, Thomas Aagaard Jensen